Evidence map›Paper›PMID 36474576›Full record

ArticleIranian journal of basic medical sciences2022

Dipeptidyl peptidase-4 inhibitor: Sitagliptin down-regulated toll-like receptor 4 signaling pathway to reduce uterine injury in rats.

Remon Roshdy Rofaeil, Sabreen Mahmoud Ahmed, Haitham Ahmed Bahaa, Ahmad Mahran, Nermeen N Welson, Walaa Yehia Abdelzaher

Open access · greenAbstract read
In one paragraph

Article in Iranian journal of basic medical sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 77% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Remon Roshdy RofaeilDepartment of Pharmacology, Faculty of Medicine, Minia University, Minia, Egypt.
Sabreen Mahmoud AhmedDepatment of Human Anatomy and Embryology, Faculty of Medicine, Minia University, delegated to Deraya University-New Minia City, Egypt.
Haitham Ahmed BahaaDepartment of Obstetrics and Gynecology, Faculty of Medicine, Minia University. Minia, Egypt.
Ahmad MahranDepartment of Obstetrics and Gynecology, Faculty of Medicine, Minia University. Minia, Egypt.
Nermeen N WelsonDepartment of Forensic Medicine and Clinical Toxicology, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt.
Walaa Yehia AbdelzaherDepartment of Pharmacology, Faculty of Medicine, Minia University, Minia, Egypt.
Minia University · EGBeni-Suef University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Uterine ischemia is a common problem with ongoing controversy about its pathogenesis and prevention. The present study aimed to investigate the protective role of sitagliptin against uterine ischemia-reperfusion injury (IRI). Materials and Methods: Rats were allocated into 4 groups: control, sitagliptin (SIT) (5 mg/kg), IR; ischemia was induced followed by reperfusion, and IR+SIT; SIT was administered 1 hr before IRI. Uteri were removed for histopathological and biochemical observations. Malondialdehyde (MDA), total nitrites (NOx), reduced glutathione (GSH), superoxide dismutase (SOD) activity, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and toll-like receptor 4 (TLR4) were all measured. Hematoxylin and eosin (H&E) stain, Periodic acid-Schiff stain (PAS), and caspase-3 immunostaining were applied. Results: In the IR+SIT group; NOx, GSH, and SOD activities increased significantly. Meanwhile, the levels of MDA, TNF-α, IL-6, TLR4, and caspase-3 immunoexpression showed a significant reduction, as compared with the IR group. In the IR+SIT group, an improvement in the histopathological picture was noticed. Conclusion: The results showed that sitagliptin confers protection against uterine IRI through anti-oxidant, anti-inflammatory, and anti-apoptotic effects with a possible role for TLR4.

Indexed as

Anti-apoptoticAnti-inflammatorySitagliptinToll-like receptor 4Uterine ischemia

Identifiers

PMID36474576
PMCPMC9699943
OpenAlexW4310956359

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.